Production processes for highly viable, engraftable human chondrocytes from stem cells
AssigneeUniversity of Southern California
InventorDenis Evseenko
Life of this patent
Estimating the term…
Abstract
The disclosure provides for production processes for directed differentiation of stem cells into chondrocytes in fully defined animal free conditions, and uses thereof, including for focal repair of articular cartilage.
Claims29
A process to produce highly viable, engraftable human chondrocytes from pluripotent stem cells, comprising:
- culturing stem cells on laminin coated tissue culture vessel(s) comprising a serum-free, stabilized cell culture medium for pluripotent stem cells;
- transferring the stem cells to a 3D condition/spin culture system and culturing the stem cells in a medium for 5 days or more, wherein the medium comprises a serum-free, stabilized cell culture medium for pluripotent stem cells, and a ROCK inhibitor;
- differentiating the stem cells to chondrocyte-like cells by culturing the stem cells under the following conditions:
- (a) culturing the stem cells in a mesoderm induction differentiation medium for 3 days or more, wherein the mesoderm induction differentiation medium comprises a chemically defined, serum-free hematopoietic cell medium, ROCK inhibitor, Wnt3a, Activin A, and FGF2;
- (b) culturing the stem cells in a MI-B differentiation medium for 3 days or more, wherein the MI-B differentiation medium comprises a chemically defined, serum-free hematopoietic cell medium, Wnt3a, Noggin, and FGF2;
- (c) culturing the stem cells in chondrogenic induction differentiation medium A for 3 days or more, wherein the chondrogenic differentiation medium comprises a chemically defined, serum-free hematopoietic cell medium, FGF2, and BMP4;
- sorting the differentiated stem cells by using magnetic cell separation to identify CD309 and CD326 negative cells, which are collected;
- culturing the CD309 and CD326 negative cells in chondrogenic induction differentiation medium B for seven days or more to form chondrocytes, wherein chondrogenic induction differentiation medium B comprises a chemically defined, serum-free hematopoietic cell medium, FGF2, IGF1, SHH, BMP4, ROCK inhibitor, and antimicrobials;
- culturing the chondrocytes in maintenance media for 7 days or more;
- wherein the maintenance media comprises a chemically defined, serum-free hematopoietic cell medium, FGF2, IGF1, LIF, TGF-β1, BMP4, and antimicrobials;
- optionally, treating the chondrocytes with an agent or compound that enhances anabolism, extracellular matrix secretion, promotes cell survival and or proliferation, reduces catabolismand/or reduces degeneration of extracellular matrix in chondrocytes;
- and
- optionally, cryopreserving the chondrocytes with collagen membranes in a defined, serum-free, and animal component-free freezing medium that comprises a ROCK inhibitor.
3-4. (canceled).
(canceled).
A method of producing a cartilage composition comprising, inducing differentiation of a stem cell culture comprising:
- (a) culturing stem cell aggregates in mesoderm induction media A (MI-A) for 2-5 days, wherein the MI-A media comprises a chemically defined, serum-free hematopoietic cell medium containing Rock Inhibitor (10 uM), Wnt3a (10 ng/ml), bFGF (10 ng/ml) and activin A (10 ng/ml);
- (b) replacing the media of (a) with mesoderm induction media B (MI-B) and culturing the cell aggregates for 2-5 days, wherein the MI-B media comprises a chemically defined, serum-free hematopoietic cell medium containing Wnt3a (10 ng/ml), bFGF (10 ng/ml) and Noggin (50 ng/ml);
- inducing chondrocyte induction comprising:
- (1) replacing the media of (b) with chondrocyte induction media A (CI-A) and culturing the cell aggregates for 2-5 days, wherein the CI-A media comprises a chemically defined, serum-free hematopoietic cell medium containing 10 ug/ml bFGF and 50 ug/ml BMP4;
- (2) culturing CD309 and CD326 negative cells from (1) in chondrogenic induction differentiation media B (CI-B) for 1-7 days to form chondrocytes, wherein CI-B media comprises a chemically defined, serum-free hematopoietic cell medium containing 10 uM Rock inhibitor, 10 ng/ml IGF-1, 10 ng/ml bFGF, 50 ng/ml BMP4 and 25 ng/ml SHH, (i) seeding the cells obtained in (2) on a collagen membrane and culturing with maintenance media, wherein the maintenance media comprises a chemically defined, serum-free hematopoietic cell medium containing 10 ng/ml IGF-1, 10 ng/ml bFGF, 50 ng/ml LIF, 10 ng/ml TGFb1 and 1 ng/ml BMP4, wherein the media is changed as needed,
- thereby obtaining a cartilage composition.
(canceled).
16-20. (canceled).
A population of isolated cells, wherein the cells can differentiate into chondrocytes and wherein the cells express the markers COL2A1, SOX5/6/9, and ACAN.
Dependencies are inferred from the claim text.